Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Sukaina Virji
Aduro Biotech's scientists have a long association with Merck & Co's Keytruda, and things have come full circle as the small biotech's lead anticancer shows promise in combination with the high-profile checkpoint inhibitor.
Merck of Germany has developed a new genome editing tool that it believes improves on the popular, but IP battle-worn, CRISPR technology. How this will affect the existing IP landscape is as yet unknown.
Analysts' views on what the Humira formulation patent loss this week could mean for the launch timing of a biosimilar to AbbVie's main revenue driver vary.
Interview With J&J’s CMO Dr Joanne Waldstreicher On Internal And External Challenges To Sharing Clinical Trial Data
"Everything different and worthwhile comes with its challenges," Johnson & Johnson’s chief medical officer, Joanne Waldstreicher, told the Pink Sheet's Sukaina Virji in an interview about how the company went about engaging in initiatives to share its clinical trial data and make drugs available for compassionate use.
Biotech mourns the loss of one of its giants.
The failure earlier this week of Roche's Tecentriq in second line bladder cancer left both the company and analysts surprised. Bladder cancer is a competitive space with a number of other immune-oncology products at or close to market. What does the Tecentriq result mean for them?